License

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024

Retrieved on: 
Mercredi, mai 1, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Doctor of Philosophy, PFS, Paranal Observatory, Table, License, Summit, Investment, ELCC, Progression-free survival, Research, Intraparenchymal hemorrhage, Immunotherapy, Trial of the century, Webcast, Cohort, Forecasting, PD-1, NGS, TKI, Patient, GRAIL, Brain, SMMT, Neoplasm, EGFR, VEGF, GAAP, Royal institute, Neuro, Lung cancer, Pharmaceutical industry

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024.
  • In January 2024, followed by a presentation at ELCC 2024 in March 2024, Akeso announced updates from its Phase II AK112-201 trial data.
  • Also at ELCC 2024, Summit and Akeso highlighted promising ivonescimab Phase II data in NSCLC patients with brain metastases.
  • Operating cash outflow for the three months ended March 31, 2024 and 2023 was $30.1 million and $13.1 million, respectively.

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer

Retrieved on: 
Jeudi, avril 11, 2024
Sale, License, NVS, ARVN, Goldman Sachs, Research, Prostate cancer, Patient, PROTAC, Pharmaceutical industry

NEW HAVEN, Conn., April 11, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it has entered into an exclusive strategic license agreement with Novartis (NYSE: NVS) for the worldwide development and commercialization of ARV-766, Arvinas’ second generation PROTAC® androgen receptor (AR) degrader for patients with prostate cancer. The transaction also includes an asset purchase agreement for the sale of Arvinas’ preclinical AR-V7 program to Novartis.

Key Points: 
  • The transaction also includes an asset purchase agreement for the sale of Arvinas’ preclinical AR-V7 program to Novartis.
  • “We believe the expertise and scale of Novartis will broaden the development of ARV-766 and its potential to be a first- and best-in-class treatment for patients with prostate cancer.
  • Under the License Agreement, Arvinas is eligible to receive additional development, regulatory, and commercial milestones of up to $1.01 billion, as well as tiered royalties for ARV-766.
  • Goldman Sachs & Co. LLC is acting as the exclusive financial advisor to Arvinas.

ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M

Retrieved on: 
Mercredi, avril 10, 2024
Use, BioLite, Ophthalmology, Polysaccharide, Pancreatic cancer, License, Dietary supplement, Partnership, IND, CNS, Non-small-cell lung cancer, CDMO, Knowledge, Investigational New Drug, Therapy, Royalty payment, Field, Edible, Myelodysplastic syndrome, Triple-negative breast cancer, MDS, Ergosterol, NSCLC, TNBC, US FDA, Pharmaceutical industry

The Investigational New Drug (IND) application proposed the clinical investigation of BLEX 404 as the primary active ingredient.

Key Points: 
  • The Investigational New Drug (IND) application proposed the clinical investigation of BLEX 404 as the primary active ingredient.
  • [1]
    "We are thrilled to announce that the term sheet for a potential groundbreaking licensing deal with OncoX has been successfully executed.
  • This licensing deal marks a significant milestone for ABVC and OncoX, affirming their commitment to excellence and shared vision for the future.
  • ABVC urges its shareholders to sign up on the Company's website for the latest news alerts; visit https://abvcpharma.com/?page_id=17707

Mountain Valley MD Announces Acquisition of Exclusive License for Agrarius, Launch of Performance Guarantee Program

Retrieved on: 
Mercredi, avril 24, 2024
Professional Services, Health, Pharmaceutical, Agriculture, Other Science, Natural Resources, Research, Fitness & Nutrition, Environment, Science, Finance, USD, Sale, Agreement, Climate change, Risk, Performance, License fee, Farmer, Photosynthesis, License, CAD, AC, Nutrient, Growth, FRA

"Securing the exclusive rights to distribute and sell the Agrarius product in North and South America, Central America, Mexico, and the Caribbean is viewed as a tremendous accomplishment and a major milestone for MVMD," explained Dennis Hancock, President & CEO of Mountain Valley MD.

Key Points: 
  • "Securing the exclusive rights to distribute and sell the Agrarius product in North and South America, Central America, Mexico, and the Caribbean is viewed as a tremendous accomplishment and a major milestone for MVMD," explained Dennis Hancock, President & CEO of Mountain Valley MD.
  • MVMD and AC will share equally in the guarantee such that MVMD will not be required to pay AC for the Agrarius product until the Performance Threshold has been met.
  • "The Performance Guarantee Program completely aligns our interests with those of our farming clients to ensure optimized crop performance while limiting the clients’ risk in this unique pay-for-performance model," continued Hancock.
  • The Agrarius product has been designed to activate a plants’ “defense mechanisms” at the cellular level, without the actual stress factor.

Celerium Enhances CMMC Compliance Education Offerings with Addition of CCA (Certified CMMC Assessor) Training Materials and Updated DIB Contractors Course

Retrieved on: 
Jeudi, avril 25, 2024
Online, Certification, DIB, Compromise, CCP, License, CDN, CUI, Curriculum, CCA, Access control, Computer security, AC, Incident, CMMC, Department of Defence

TORRANCE, Calif., April 25, 2024 /PRNewswire/ -- Celerium Inc. today announced the availability of its Certified CMMC Assessor (CCA) course training materials for Licensed Training Providers to use in training CMMC certified professionals and CMMC assessors. These materials were created by Celerium's team of experienced compliance implementers and were approved by the U.S. Department of Defense (DoD). Celerium is authorized to create these training materials as an official Licensed Publishing Partner with the Cyber Accreditation Body (Cyber AB).

Key Points: 
  • TORRANCE, Calif., April 25, 2024 /PRNewswire/ -- Celerium Inc. today announced the availability of its Certified CMMC Assessor (CCA) course training materials for Licensed Training Providers to use in training CMMC certified professionals and CMMC assessors.
  • Celerium is authorized to create these training materials as an official Licensed Publishing Partner with the Cyber Accreditation Body (Cyber AB).
  • Defense Industrial Base (DIB) companies seeking CMMC certification can use this online, self-guided training course to guide CMMC implementation and prepare for CMMC assessment.
  • Certified CMMC Professional (CCP) and Certified CMMC Assessor (CCA) training materials for Licensed Training Providers to use in training future CMMC assessors.

Travelzoo Reports First Quarter 2024 Results

Retrieved on: 
Mercredi, avril 24, 2024
License, Nature, Social media, Travel, Jack's Flight Club, Operating cost, Acquisition, Jack's, Advertising, GAAP, Growth, Airline

NEW YORK, April 24, 2024 /PRNewswire/ -- Travelzoo® (NASDAQ: TZOO):

Key Points: 
  • NEW YORK, April 24, 2024 /PRNewswire/ -- Travelzoo® (NASDAQ: TZOO):
    Travelzoo, the club for travel enthusiasts, today announced financial results for the first quarter ended March 31, 2024.
  • Net income attributable to Travelzoo was $4.2 million for Q1 2024, or $0.31 per share, compared with $0.23 in the prior-year period.
  • Net income attributable to Travelzoo from continuing operations was $4.2 million for Q1 2024, or $0.31 per share, compared with $0.23 in the prior-year period.
  • Travelzoo will host a conference call to discuss first quarter 2024 results today at 11:00 a.m.

700 Credit Introduces Driver's License Authentication Integration with the iTapMenu F&I Platform

Retrieved on: 
Mardi, avril 23, 2024
License, DMV, DocuSign, Partnership, Red flag, DMS, Rule, Credit, Stripe, Online shopping

FARMINGTON HILLS, Mich., April 23, 2024 /PRNewswire-PRWeb/ -- 700 Credit, LLC, the vehicle industry's leading provider of credit reports, compliance solutions, soft pull, identity verification and fraud detection platforms, today announced its integration with iTapMenu, an F&I Menu platform that offers e-signature and e-payment solutions. The new integration includes the Mobile Driver's License Authentication Platform (QuickScan), Red Flag and OFAC compliancy tools. iTapMenu™ is an F&I presentation solution utilized by hundreds of automotive, powersport, RV, and marine dealerships in the US and Canada. iTapMenu offers the first ever live video feed built directly into F&I Menu software called FandEye™ to solve the remote delivery issue and offers many direct integrations with high-profile vendors including DMS providers, 700Credit, DocuSign, Stripe, and Kelley Blue Book. iTapMenu has integrated the 700Credit Mobile Driver's License Authentication Platform (QuickScan) a powerful mobile document scanner that provides dealerships real-time confirmation of the legitimacy of a customer's driver's license and identity. In just minutes, dealerships can receive powerful information on their consumers to detect and prevent fraud before it becomes costly. The information and images captured can then be automatically loaded into the Digital Deal Jacket. In addition, the QuickScan platform provides a DMV look-up, device verification, synthetic ID fraud detection, identity verification and selfie comparison to driver's license image.

Key Points: 
  • FARMINGTON HILLS, Mich., April 23, 2024 /PRNewswire-PRWeb/ -- 700 Credit, LLC, the vehicle industry's leading provider of credit reports, compliance solutions, soft pull, identity verification and fraud detection platforms, today announced its integration with iTapMenu, an F&I Menu platform that offers e-signature and e-payment solutions.
  • The new integration includes the Mobile Driver's License Authentication Platform (QuickScan), Red Flag and OFAC compliancy tools.
  • iTapMenu™ is an F&I presentation solution utilized by hundreds of automotive, powersport, RV, and marine dealerships in the US and Canada.
  • iTapMenu has integrated the 700Credit Mobile Driver's License Authentication Platform (QuickScan) a powerful mobile document scanner that provides dealerships real-time confirmation of the legitimacy of a customer's driver's license and identity.

Chiesi Group's 2023 Revenue Surpasses €3 Billion Mark, Reflecting 10% Growth Year-on-Year (+12% @CER), Underlining Commitment to Innovative, Sustainable Practices

Retrieved on: 
Lundi, avril 22, 2024
Carbon, Science, Corporation, Enzyme replacement therapy, FDA, AIR, License, International, RARE, Investment, Climate, Fabry disease, Climate change, CER, B Corporation (certification), CDP, Partnership, Empowerment, Alpha-mannosidosis, Parent, CARE, Chronic obstructive pulmonary disease, Environment, Culture, Benefit corporation, Patient, Science Based Targets initiative, Bronchiectasis, Acquisition, Caregiver, Epidermolysis bullosa, GHG, Place of birth, Health, Neonatology, Ethics, Asthma, RDS, Infant respiratory distress syndrome, Growth, Carbon Disclosure Project, COPD, Pharmaceutical industry

PARMA, Italy, April 22, 2024 /PRNewswire/ -- In 2023, Chiesi, a research-oriented international biopharmaceutical group headquartered in Parma (Italy), with 31 affiliates worldwide, showcased the efficacy of its operating model centred around shared value, sustainability, and high ethical standards. Through this approach, Chiesi continues to deliver tangible benefits for patients, people, and the planet.

Key Points: 
  • Chiesi's fixed triple formulation for the treatment of asthma and COPD (Chronic Obstructive Pulmonary Disease) achieved a 27% @CER growth.
  • Also, in 2023 it was introduced in China, presenting a pivotal opportunity for growth and expanding access to treatment for more patients.
  • In March 2023, Chiesi enriched its AIR portfolio thanks to the partnership with Affibody AB to develop and commercialize innovative treatments for respiratory diseases.
  • In November 2023, Chiesi signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel solution for bronchiectasis.

Brazil Potash Receives Mine Installation License to Start Project Construction of the Autazes Potash Project in Brazil

Retrieved on: 
Mardi, avril 9, 2024
Mining, Farmer, Amazon, Poultry, Risk, Soybean, Indigenous, Plant, License, Fertilizer, Government

MANAUS, Brazil, April 09, 2024 (GLOBE NEWSWIRE) -- Brazil Potash Corp. (“Brazil Potash” or the “Company”) is excited to announce the Amazon State Environmental Protection Institute (IPAAM), has granted the mine Installation License for the Autazes Potash Project (the “Project”) to the 100% owned Brazilian subsidiary Potassio do Brasil, allowing for construction to commence.

Key Points: 
  • MANAUS, Brazil, April 09, 2024 (GLOBE NEWSWIRE) -- Brazil Potash Corp. (“Brazil Potash” or the “Company”) is excited to announce the Amazon State Environmental Protection Institute (IPAAM), has granted the mine Installation License for the Autazes Potash Project (the “Project”) to the 100% owned Brazilian subsidiary Potassio do Brasil, allowing for construction to commence.
  • The Company expects to start construction with the awarding of contracts for mine surface works and shaft construction.
  • Now, with the License approval, Brazil can produce this essential mineral for its farmers in country, by-passing the risk and costs of imports.
  • Potash is extremely important to efficiently grow food as it strengthens the stem of plants to make them more resilient to stresses caused by drought, extreme temperatures, and insect infestation.

Scilex Holding Company Announces a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex’s Filing of a sNDA with the FDA Seeking to Expand the Label for its FDA-Approved Liquid Colchici

Retrieved on: 
Mercredi, mars 20, 2024
Paragraph, Gout, Vexatious litigation, Shanda, Chronic pain, Settlement, PALO, Justice, Takeda, License, FDA, Federal Trade Commission, Nursing

That litigation arose from Scilex’s filing of a sNDA with the FDA seeking to expand the label for its FDA-approved liquid colchicine product, Gloperba®, a preventive treatment for gout.

Key Points: 
  • That litigation arose from Scilex’s filing of a sNDA with the FDA seeking to expand the label for its FDA-approved liquid colchicine product, Gloperba®, a preventive treatment for gout.
  • As part of the Settlement Agreement, the Scilex Parties entered into a License Agreement with Takeda granting the Company and its affiliates a non-exclusive license to certain patents owned by Takeda.
  • The Settlement Agreement is subject to approval by the district court, and by both the Federal Trade Commission and the U.S. Department of Justice, as is required in Paragraph IV patent case settlements.
  • For more information on Scilex Holding Company, refer to www.scilexholding.com .